IMVT Immunovant, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1764013 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-9.5%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-86.5%
ROA-75.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets13.7%
Debt / equity0.00x
Current ratio7.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-17.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $456.66M | $360.92M | $212.93M | $160.26M | $101.81M |
| SG&A expense | $76.24M | $77.23M | $57.28M | $48.02M | $54.23M |
| Pretax income | -$505.39M | -$412.95M | -$258.77M | -$210.95M | -$156.81M |
| Income tax | $215,000 | $891,000 | $567,000 | $9,000 | -$84,000 |
| Net income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M |
| EPS (basic) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| EPS (diluted) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| Weighted avg. shares (diluted) | 182.42M | 151.57M | 138.10M | 123.08M | 109.68M |
| Banking | |||||
| Net interest income | — | — | $24.95M | $7.58M | $0 |
| Balance sheet | |||||
| Cash & equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M |
| Receivables | $1.13M | $2.08M | $5.34M | $700,000 | $12.23M |
| Current assets | $948.82M | $767.66M | $665.77M | $404.33M | $512.93M |
| PP&E, net | $443,000 | $844,000 | $462,000 | $333,000 | $330,000 |
| Total assets | $957.01M | $776.22M | $666.37M | $405.84M | $515.56M |
| Current liabilities | $104.42M | $68.78M | $48.61M | $43.30M | $44.52M |
| Total liabilities | $104.42M | $68.78M | $48.61M | $43.34M | $45.74M |
| Shareholders' equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M |
| Shares outstanding | 203.94M | 170.11M | 145.58M | 130.33M | 116.48M |
| Cash flow statement | |||||
| Operating cash flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M |
| Capital expenditure | $8,000 | $759,000 | $360,000 | $197,000 | $254,000 |
| Free cash flow | -$407.32M | -$376.63M | -$214.59M | -$188.39M | -$106.37M |
| Investing cash flow | -$8,000 | -$759,000 | -$360,000 | -$197,000 | -$254,000 |
| Financing cash flow | $595.76M | $454.49M | $472.43M | $70.89M | $200.13M |
| Depreciation & amortization | $409,000 | $377,000 | $231,000 | $193,000 | $126,000 |
| Stock-based compensation | $55.72M | $49.49M | $41.12M | $32.30M | $34.24M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.